Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 136 | 1.650 |
Why?
|
Lymphoma, T-Cell | 7 | 2021 | 64 | 1.570 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2022 | 285 | 1.340 |
Why?
|
Translocation, Genetic | 4 | 2024 | 351 | 1.340 |
Why?
|
Myelodysplastic Syndromes | 3 | 2017 | 137 | 1.000 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 123 | 1.000 |
Why?
|
Burkitt Lymphoma | 2 | 2024 | 145 | 0.900 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2022 | 43 | 0.900 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 172 | 0.860 |
Why?
|
Biomarkers, Tumor | 6 | 2024 | 1431 | 0.850 |
Why?
|
Herpesvirus 4, Human | 3 | 2022 | 659 | 0.830 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2023 | 132 | 0.740 |
Why?
|
T-Lymphocytes | 2 | 2019 | 1678 | 0.700 |
Why?
|
Lymphoma, B-Cell | 1 | 2021 | 135 | 0.690 |
Why?
|
Anemia | 1 | 2023 | 339 | 0.670 |
Why?
|
Flow Cytometry | 3 | 2017 | 804 | 0.660 |
Why?
|
Tertiary Healthcare | 1 | 2019 | 21 | 0.660 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 193 | 0.640 |
Why?
|
Hodgkin Disease | 1 | 2021 | 293 | 0.630 |
Why?
|
Lymphocyte Transfusion | 1 | 2018 | 57 | 0.610 |
Why?
|
Leukopenia | 2 | 2023 | 44 | 0.600 |
Why?
|
Lymphoproliferative Disorders | 1 | 2019 | 224 | 0.580 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2017 | 19 | 0.570 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 53 | 0.560 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2022 | 197 | 0.520 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2015 | 32 | 0.490 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2015 | 65 | 0.480 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 478 | 0.480 |
Why?
|
Philadelphia Chromosome | 1 | 2014 | 40 | 0.470 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2014 | 41 | 0.470 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 61 | 0.470 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 44 | 0.460 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2017 | 213 | 0.460 |
Why?
|
Panniculitis | 1 | 2013 | 19 | 0.440 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2022 | 133 | 0.420 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2013 | 66 | 0.420 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 87 | 0.400 |
Why?
|
Myeloproliferative Disorders | 1 | 2013 | 90 | 0.400 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2015 | 757 | 0.400 |
Why?
|
Chromosome Aberrations | 1 | 2015 | 614 | 0.390 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 2 | 2022 | 21 | 0.380 |
Why?
|
Adolescent | 13 | 2024 | 19086 | 0.350 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2012 | 200 | 0.340 |
Why?
|
Monocytes | 1 | 2012 | 347 | 0.340 |
Why?
|
Child | 12 | 2024 | 24208 | 0.330 |
Why?
|
Sarcoma, Clear Cell | 1 | 2008 | 20 | 0.300 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2024 | 532 | 0.300 |
Why?
|
Humans | 33 | 2024 | 123190 | 0.300 |
Why?
|
Gene Rearrangement | 2 | 2014 | 326 | 0.290 |
Why?
|
Bone Marrow | 3 | 2021 | 322 | 0.280 |
Why?
|
Soft Tissue Neoplasms | 1 | 2008 | 130 | 0.270 |
Why?
|
Tertiary Care Centers | 2 | 2023 | 236 | 0.250 |
Why?
|
Male | 16 | 2024 | 60020 | 0.250 |
Why?
|
Diagnosis, Differential | 5 | 2024 | 1871 | 0.240 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 1294 | 0.240 |
Why?
|
Female | 12 | 2024 | 65427 | 0.240 |
Why?
|
Biopsy, Fine-Needle | 2 | 2017 | 115 | 0.240 |
Why?
|
Primary Myelofibrosis | 2 | 2023 | 50 | 0.240 |
Why?
|
Lymph Nodes | 2 | 2019 | 375 | 0.230 |
Why?
|
Transcription Factors | 3 | 2022 | 2577 | 0.230 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 2 | 2016 | 128 | 0.230 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2024 | 78 | 0.230 |
Why?
|
Reticulocytes | 1 | 2023 | 42 | 0.220 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2024 | 100 | 0.220 |
Why?
|
Retrospective Studies | 6 | 2023 | 15979 | 0.200 |
Why?
|
Hemoglobins | 1 | 2023 | 300 | 0.200 |
Why?
|
ROC Curve | 1 | 2023 | 557 | 0.190 |
Why?
|
Cryptococcosis | 1 | 2021 | 42 | 0.190 |
Why?
|
B7-H1 Antigen | 1 | 2022 | 99 | 0.190 |
Why?
|
Drug Eruptions | 1 | 2021 | 33 | 0.190 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2022 | 105 | 0.190 |
Why?
|
Ribs | 1 | 2021 | 44 | 0.190 |
Why?
|
Adenine | 1 | 2021 | 99 | 0.190 |
Why?
|
Ligands | 1 | 2022 | 533 | 0.180 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2023 | 171 | 0.180 |
Why?
|
Child, Preschool | 6 | 2019 | 13862 | 0.180 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 250 | 0.180 |
Why?
|
Mediastinal Neoplasms | 1 | 2020 | 39 | 0.180 |
Why?
|
Down-Regulation | 4 | 2017 | 697 | 0.180 |
Why?
|
Neoplasm Staging | 2 | 2015 | 1216 | 0.170 |
Why?
|
Piperidines | 1 | 2021 | 198 | 0.170 |
Why?
|
Central Nervous System | 1 | 2021 | 253 | 0.170 |
Why?
|
Sarcoma, Myeloid | 1 | 2019 | 12 | 0.170 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 88 | 0.170 |
Why?
|
Disease Susceptibility | 1 | 2021 | 298 | 0.170 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 157 | 0.170 |
Why?
|
Testicular Neoplasms | 1 | 2020 | 133 | 0.160 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 145 | 0.160 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 2108 | 0.160 |
Why?
|
Prognosis | 3 | 2019 | 4508 | 0.160 |
Why?
|
DNA Methylation | 2 | 2016 | 991 | 0.160 |
Why?
|
Osteomyelitis | 1 | 2021 | 204 | 0.160 |
Why?
|
Biopsy | 3 | 2021 | 1239 | 0.150 |
Why?
|
Cell Proliferation | 4 | 2018 | 2308 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 1114 | 0.150 |
Why?
|
Lung Transplantation | 1 | 2021 | 316 | 0.140 |
Why?
|
Up-Regulation | 3 | 2015 | 868 | 0.140 |
Why?
|
Biopsy, Large-Core Needle | 1 | 2017 | 29 | 0.140 |
Why?
|
Image-Guided Biopsy | 1 | 2017 | 35 | 0.140 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2016 | 23 | 0.130 |
Why?
|
Megakaryocytes | 1 | 2016 | 48 | 0.130 |
Why?
|
Syndrome | 1 | 2018 | 1114 | 0.130 |
Why?
|
MicroRNAs | 2 | 2013 | 831 | 0.130 |
Why?
|
Apoptosis | 1 | 2022 | 1783 | 0.130 |
Why?
|
Protein Kinases | 1 | 2017 | 330 | 0.130 |
Why?
|
Sumoylation | 1 | 2015 | 34 | 0.130 |
Why?
|
Receptors, Somatomedin | 1 | 2015 | 25 | 0.120 |
Why?
|
Monosomy | 1 | 2015 | 24 | 0.120 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2015 | 110 | 0.120 |
Why?
|
Promoter Regions, Genetic | 2 | 2015 | 1338 | 0.120 |
Why?
|
Thrombocytopenia | 1 | 2016 | 229 | 0.110 |
Why?
|
Immunophenotyping | 1 | 2015 | 330 | 0.110 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 300 | 0.110 |
Why?
|
Immunohistochemistry | 2 | 2015 | 1684 | 0.110 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2014 | 24 | 0.110 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2013 | 14 | 0.110 |
Why?
|
Cytokines | 2 | 2021 | 1284 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 2043 | 0.110 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2013 | 23 | 0.110 |
Why?
|
Axilla | 1 | 2013 | 38 | 0.110 |
Why?
|
Genomics | 1 | 2021 | 1477 | 0.110 |
Why?
|
Protein Processing, Post-Translational | 1 | 2015 | 354 | 0.110 |
Why?
|
Lung Neoplasms | 2 | 2013 | 1582 | 0.110 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2013 | 94 | 0.100 |
Why?
|
Leukemia | 1 | 2016 | 376 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2013 | 357 | 0.100 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 2024 | 0.100 |
Why?
|
Liver | 1 | 2019 | 1735 | 0.100 |
Why?
|
RNA, Neoplasm | 1 | 2012 | 138 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2015 | 286 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 619 | 0.090 |
Why?
|
Infant | 4 | 2019 | 12323 | 0.090 |
Why?
|
STAT3 Transcription Factor | 1 | 2013 | 217 | 0.090 |
Why?
|
Recurrence | 1 | 2015 | 1420 | 0.090 |
Why?
|
Prevalence | 1 | 2017 | 2405 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 1 | 2015 | 537 | 0.090 |
Why?
|
Follow-Up Studies | 1 | 2019 | 5047 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 3098 | 0.080 |
Why?
|
Cell Survival | 3 | 2017 | 803 | 0.080 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 333 | 0.080 |
Why?
|
RNA-Binding Protein EWS | 1 | 2008 | 34 | 0.080 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2008 | 63 | 0.070 |
Why?
|
Age Factors | 1 | 2014 | 2801 | 0.070 |
Why?
|
Cell Line, Tumor | 4 | 2017 | 3288 | 0.070 |
Why?
|
Heart Transplantation | 1 | 2013 | 854 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2016 | 1875 | 0.070 |
Why?
|
Treatment Outcome | 2 | 2015 | 12102 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 519 | 0.060 |
Why?
|
Phenotype | 1 | 2015 | 4225 | 0.060 |
Why?
|
Time Factors | 1 | 2015 | 6201 | 0.060 |
Why?
|
Young Adult | 2 | 2017 | 8868 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2008 | 573 | 0.060 |
Why?
|
Mice | 5 | 2021 | 17497 | 0.050 |
Why?
|
Neoplasms | 1 | 2017 | 2767 | 0.050 |
Why?
|
Phosphorylation | 2 | 2017 | 1611 | 0.050 |
Why?
|
Perforin | 1 | 2021 | 18 | 0.050 |
Why?
|
Mutation | 3 | 2021 | 5778 | 0.050 |
Why?
|
Middle Aged | 3 | 2021 | 25976 | 0.050 |
Why?
|
Acute Disease | 1 | 2024 | 1090 | 0.050 |
Why?
|
Cell Movement | 2 | 2015 | 831 | 0.040 |
Why?
|
Cytogenetic Analysis | 1 | 2020 | 79 | 0.040 |
Why?
|
Algorithms | 2 | 2021 | 1597 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 193 | 0.040 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 184 | 0.040 |
Why?
|
Animals | 5 | 2021 | 33740 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2021 | 266 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2021 | 293 | 0.040 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 323 | 0.040 |
Why?
|
Signal Transduction | 3 | 2017 | 4508 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2022 | 811 | 0.040 |
Why?
|
Nerve Growth Factor | 1 | 2017 | 24 | 0.040 |
Why?
|
Disease Management | 1 | 2021 | 516 | 0.040 |
Why?
|
Chondrosarcoma | 1 | 2017 | 10 | 0.040 |
Why?
|
Rhabdoid Tumor | 1 | 2017 | 49 | 0.030 |
Why?
|
Bone Marrow Examination | 1 | 2016 | 14 | 0.030 |
Why?
|
Reticulin | 1 | 2016 | 8 | 0.030 |
Why?
|
Integrin beta3 | 1 | 2016 | 27 | 0.030 |
Why?
|
Sarcoma, Ewing | 1 | 2017 | 113 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 126 | 0.030 |
Why?
|
Mice, SCID | 1 | 2017 | 572 | 0.030 |
Why?
|
Jurkat Cells | 1 | 2015 | 76 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 211 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 665 | 0.030 |
Why?
|
3T3 Cells | 1 | 2015 | 129 | 0.030 |
Why?
|
Protein Stability | 1 | 2015 | 167 | 0.030 |
Why?
|
Bone and Bones | 1 | 2017 | 262 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 2015 | 91 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 297 | 0.030 |
Why?
|
Aged | 3 | 2021 | 19068 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 878 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2017 | 257 | 0.030 |
Why?
|
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2013 | 5 | 0.030 |
Why?
|
Leukocytosis | 1 | 2014 | 42 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2014 | 67 | 0.030 |
Why?
|
Survival Analysis | 1 | 2017 | 1470 | 0.030 |
Why?
|
Karyotyping | 1 | 2014 | 329 | 0.030 |
Why?
|
Imines | 1 | 2013 | 9 | 0.030 |
Why?
|
Protein Binding | 1 | 2017 | 1743 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2014 | 159 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 2533 | 0.030 |
Why?
|
Tyrosine | 1 | 2013 | 152 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2013 | 127 | 0.030 |
Why?
|
Cohort Studies | 1 | 2021 | 4708 | 0.030 |
Why?
|
Neprilysin | 1 | 2012 | 19 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2013 | 321 | 0.020 |
Why?
|
Biomarkers | 1 | 2021 | 2943 | 0.020 |
Why?
|
Chemotaxis | 1 | 2012 | 55 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 287 | 0.020 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2014 | 371 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 515 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 667 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 256 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2012 | 623 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2017 | 2851 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 467 | 0.020 |
Why?
|
Nitric Oxide | 1 | 2013 | 432 | 0.020 |
Why?
|
Transfection | 1 | 2012 | 1068 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2012 | 294 | 0.020 |
Why?
|
Cell Line | 1 | 2015 | 2779 | 0.020 |
Why?
|
Binding Sites | 1 | 2012 | 1292 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2015 | 2820 | 0.020 |
Why?
|
Pediatrics | 1 | 2017 | 1139 | 0.020 |
Why?
|
Base Sequence | 1 | 2012 | 3093 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2015 | 3717 | 0.020 |
Why?
|
Adult | 1 | 2023 | 29035 | 0.010 |
Why?
|